Hua Hong Semiconductor Stock Surges to Multi-Year High Amid AI Boom 
Maersk Q1 Earnings Beat Expectations as Iran Conflict Clouds Shipping Outlook 
Hugo Boss Beats Q1 Profit Expectations Despite Market Headwinds 
Orsted Q1 EBITDA Beats Expectations Despite U.S. Impairments 
Rivian Hints at New R2 Variants as Production Ramps Up Ahead of 2027 Launch 
China Banks Halt New Loans to Sanctioned Refineries Amid U.S.-Iran Oil Crackdown 
BHP Attracts AI-Focused Investors as Copper Demand Surges 
Strategy Reports Q1 Loss as Bitcoin Holdings Trigger $14.46 Billion Unrealized Hit 
Hantavirus Cruise Ship Outbreak Triggers Global Health Alert 
Strategy Hints at Bitcoin Sales to Cover Dividends After Massive Q1 Loss 
Agentic AI Boom to Drive Massive Growth in CPU Market, UBS Says 
AMD Q1 Earnings Surge on AI Demand, Stock Jumps After Strong Guidance 
Aker BP Q1 Profit Jumps on Higher Oil Prices and Asset Reversal 
Volvo Car Sales Drop 10% in Early 2026 Despite Growth in Electric Vehicles 
Apple Explores Intel and Samsung Partnerships to Diversify Chip Supply Chain 
Infineon Raises 2026 Outlook as AI Data Center Chip Demand Surges 
Shell Q1 Profit Surges to Two-Year High as Dividend Rises Despite War-Driven Debt Pressure 
SAN DIEGO, April 27, 2018 -- AnaptysBio, Inc. (Nasdaq:ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that that company will participate in the following investor conferences in May:
- William Blair 2nd Annual Late Stage Therapeutics Conference on Thursday, May 3, 2018 in New York
- Bank of America Merrill Lynch Health Care Conference on Wednesday, May 16, 2018 at 4:20 p.m. PT in Las Vegas
A webcast of the Bank of America Merrill Lynch Health Care Conference presentation will be available through the investor section of the AnaptysBio website. A replay of the webcast will be available for 90 days following the event.
About AnaptysBio
AnaptysBio is a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation. The company’s proprietary anti-inflammatory pipeline includes its anti-IL-33 antibody (ANB020) for the treatment of moderate-to-severe adult atopic dermatitis, moderate-to-severe baseline adult peanut allergy and severe adult eosinophilic asthma; its anti-IL-36R antibody (ANB019) for the treatment of rare inflammatory diseases, including generalized pustular psoriasis (GPP) and palmoplantar pustulosis (PPP), previously referred to as palmo-plantar pustular psoriasis; and a portfolio of checkpoint receptor agonist antibodies for the treatment of certain autoimmune diseases where immune checkpoint receptors are insufficiently activated, which have demonstrated efficacy in an animal model of graft-versus-host disease. AnaptysBio’s antibody pipeline has been developed using its proprietary somatic hypermutation (SHM) platform, which uses in vitro SHM for antibody discovery and is designed to replicate key features of the human immune system to overcome the limitations of competing antibody discovery technologies. AnaptysBio has also developed multiple therapeutic antibodies in an immuno-oncology partnership with TESARO and an inflammation partnership with Celgene, including an anti-PD-1 antagonist antibody (TSR-042), an anti-TIM-3 antagonist antibody (TSR-022) and an anti-LAG-3 antagonist antibody (TSR-033), which are currently under clinical development with TESARO, and an anti-PD-1 checkpoint agonist antibody (CC-90006) currently in the clinic with Celgene.
Contact:
Monique Allaire
THRUST Investor Relations
617.895.9511
[email protected]
Chelcie Lister
THRUST Investor Relations
910.777.3049
[email protected]
